Alarm (ALRM) Receives a Hold from Jefferies
Jefferies analyst Samad Samana maintained a Hold rating on Alarm (ALRM – Research Report) today and set a price target of $65.00. The company's shares closed today at $56.50.
Confident Investing Starts Here:
According to TipRanks, Samana is a 4-star analyst with an average return of 4.6% and a 49.64% success rate. Samana covers the Technology sector, focusing on stocks such as HubSpot, ServiceNow, and Shopify.
In addition to Jefferies, Alarm also received a Hold from William Blair's Stephen Sheldon in a report issued on May 9. However, on May 15, Maxim Group reiterated a Buy rating on Alarm (NASDAQ: ALRM).
The company has a one-year high of $71.98 and a one-year low of $48.23. Currently, Alarm has an average volume of 397.4K.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALRM in relation to earlier this year. Earlier this month, Daniel Ramos, the Chief Legal and Compliance Officer; SVP, Corporate Operations of ALRM sold 6,890.00 shares for a total of $413,813.40.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The Pre-Funded Warrants are immediately exercisable, and may be exercised at any time after their original issuance. The Series A Warrants are immediately exercisable any time after their original issuance until December 31, 2025. The Series B Warrants will be exercisable beginning on October 1, 2025, or earlier if certain thresholds are met, until June 3, 2030. The Series A and B Warrants will immediately expire in proportion to the extent that the corresponding Pre-Funded Warrant offered hereby is exercised on or prior to September 30, 2025, subject to certain exceptions. The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an aggregate of $130 million of additional proceeds if the Series A Warrants and Series B Warrants are exercised in full for cash. The financing was co-led by BVF Partners and Coastlands Capital, and included participation from Aberdeen Investments, Adage Capital Partners LP, Janus Henderson Investors, and other institutional investors. Leerink Partners acted as the sole bookrunner for the offering. B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-managers, and William Blair & Company, L.L.C. served as financial advisor to the Company. The Company intends to use the net proceeds from the offering to fund its clinical trials and operations and for other general corporate purposes. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the receipt of additional proceeds from the offering if the Series A Warrants and Series B Warrants are exercised in full for cash, Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; and the development and commercial potential of any product candidates of the Company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes, the risk that warrants issued in this offering will not be exercised for cash in the future. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the Company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartzs+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ View original content to download multimedia: SOURCE Immunic, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Intel and Microsoft Lead Retreat as Massive Tech Job Sell-Off Slows
June 3 - Tech sector job cuts have eased in 2025, marking a second consecutive year of declines. Layoffs in the sector have slowed, with 137 companies cutting a total of 62,114 positions halfway through the year, according to a report by Warning! GuruFocus has detected 7 Warning Signs with INTC. If that pace continues, the sector will see about 145,080 layoffs this year, down from 152,922 in 2024 and far below the 264,220 recorded in 2023. The largest reductions came at Intel (NASDAQ:INTC), which in April said it would trim over 20% of its workforce under new CEO Lip-Bu Tan. Reports indicate roughly 22,000 roles were eliminated, accounting for more than one-third of all tech layoffs so far in 2025. Microsoft (NASDAQ:MSFT) followed in mid-May, cutting its global headcount by 3%, or about 6,000 positions. We continue to implement organizational changes necessary to best position the company for success in a dynamic marketplace, a Microsoft spokesperson told the media. Meta Platforms (NASDAQ:META) enacted a performance-based reduction in February, removing around 3,600 jobs. CEO Mark Zuckerberg said in January he planned to eliminate 5% of roles rated as low performers, with plans to rehire later. Overall, 2025 layoffs may fall below last year's total as tech firms strive to balance growth with cost control. This article first appeared on GuruFocus.
Yahoo
8 minutes ago
- Yahoo
CrowdStrike's (NASDAQ:CRWD) Q1 Earnings Results: Revenue In Line With Expectations But Stock Drops
Cybersecurity company CrowdStrike (NASDAQ:CRWD) met Wall Street's revenue expectations in Q1 CY2025, with sales up 19.8% year on year to $1.10 billion. On the other hand, next quarter's revenue guidance of $1.15 billion was less impressive, coming in 1% below analysts' estimates. Its non-GAAP profit of $0.73 per share was 10.6% above analysts' consensus estimates. Is now the time to buy CrowdStrike? Find out in our full research report. Revenue: $1.10 billion vs analyst estimates of $1.11 billion (19.8% year-on-year growth, in line) Adjusted EPS: $0.73 vs analyst estimates of $0.66 (10.6% beat) Adjusted Operating Income: $201.1 million vs analyst estimates of $177.9 million (18.2% margin, 13.1% beat) The company reconfirmed its revenue guidance for the full year of $4.77 billion at the midpoint Adjusted EPS guidance for the full year is $3.50 at the midpoint, beating analyst estimates by 1.3% Operating Margin: -11.3%, down from 0.8% in the same quarter last year Free Cash Flow Margin: 25.3%, up from 22.7% in the previous quarter Annual Recurring Revenue: $4.4 billion at quarter end, up 20.7% year on year Market Capitalization: $119.3 billion 'We started the fiscal year with record Q1 large deal and MSSP momentum alongside sustained 97% gross retention and consistently strong net retention as the market consolidates on Falcon as its cybersecurity platform of choice for the agentic AI era,' said George Kurtz, Founder and CEO. Founded by George Kurtz, the former CTO of the antivirus company McAfee, CrowdStrike (NASDAQ:CRWD) provides cybersecurity software that protects companies from breaches and helps them detect and respond to cyber attacks. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, CrowdStrike's sales grew at an exceptional 36.2% compounded annual growth rate over the last three years. Its growth surpassed the average software company and shows its offerings resonate with customers, a great starting point for our analysis. This quarter, CrowdStrike's year-on-year revenue growth was 19.8%, and its $1.10 billion of revenue was in line with Wall Street's estimates. Company management is currently guiding for a 19.1% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 21.6% over the next 12 months, a deceleration versus the last three years. Still, this projection is commendable and indicates the market sees success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. While reported revenue for a software company can include low-margin items like implementation fees, annual recurring revenue (ARR) is a sum of the next 12 months of contracted revenue purely from software subscriptions, or the high-margin, predictable revenue streams that make SaaS businesses so valuable. CrowdStrike's ARR punched in at $4.4 billion in Q1, and over the last four quarters, its growth was impressive as it averaged 25.9% year-on-year increases. This performance aligned with its total sales growth and shows that customers are willing to take multi-year bets on the company's technology. Its growth also makes CrowdStrike a more predictable business, a tailwind for its valuation as investors typically prefer businesses with recurring revenue. The customer acquisition cost (CAC) payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it's the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability. CrowdStrike is quite efficient at acquiring new customers, and its CAC payback period checked in at 33.2 months this quarter. The company's rapid recovery of its customer acquisition costs indicates it has a strong brand reputation, giving it more resources pursue new product initiatives while maintaining the flexibility to increase its sales and marketing investments. It was great to see CrowdStrike beat convincingly on operating profit this quarter. Looking ahead, guidance was solid. The company's EPS guidance for next quarter topped analysts' expectations, and its full-year EPS guidance slightly exceeded Wall Street's estimates as well. On the other hand, its revenue guidance for next quarter slightly missed and its full-year revenue guidance was just in line with Wall Street's estimates. Overall, this was a mixed quarter and not enough for the high expectations around the stock (as evidenced by the 52-week high right before reporting and a 40+% stock price appreciation year-to-date before the print). The stock traded down 6.2% to $458.72 immediately following the results. Is CrowdStrike an attractive investment opportunity at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
